Home › Funds › Lynx1 Capital Management LP › CCCC
Lynx1 Capital Management LP position in CCCC
C4 THERAPEUTICS INC · Health Care
Lynx1 Capital Management LP reported holding 7,530,915 shares of CCCC (C4 THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$25.1M, representing 3.88% of its reported portfolio and ranking #4 among its reported holdings. Lynx1 Capital Management LP has disclosed CCCC holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Lynx1 Capital Management LP's CCCC position evolved
Lynx1 Capital Management LP first disclosed a stake in CCCC in Q3 2023 at 1,019,230 shares (US$1.9M). The position peaked in Q3 2024 at 6,880,527 shares, worth US$39.2M. Across 13 filings, Lynx1 Capital Management LP increased the stake 6 time(s), trimmed it 1 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 7,530,915 shares valued at US$25.1M — an increase of 204,224 shares quarter over quarter.. Notable position changes include a 208% increase in Q4 2023 (shares rose 45% over the following quarter), a 89% increase in Q2 2024 (shares rose 23% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.02M | $1.90M | New |
| Q4 2023 | 3.13M | $17.71M | Add |
| Q1 2024 | 3.63M | $29.70M | Add |
| Q2 2024 | 6.88M | $31.79M | Add |
| Q3 2024 | 6.88M | $39.22M | Hold |
| Q4 2024 | 6.85M | $24.67M | Hold |
| Q1 2025 | 7.10M | $11.36M | Add |
| Q2 2025 | 7.10M | $10.15M | Hold |
| Q3 2025 | 7.10M | $15.76M | Hold |
| Q4 2025 | 7.10M | $13.56M | Hold |
| Q1 2026 | 7.00M | $18.41M | Reduce |
| Q2 2026 | 7.33M | $34.22M | Add |
| Q3 2026 | 7.53M | $25.08M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CCCC and 13F data
CCCC (C4 THERAPEUTICS INC) is a Health Care company. 41 other funds we track also report a position in CCCC — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$27.3M), Bain Capital Life Sciences Investors, LLC (US$23.9M), Boxer Capital Management, LLC (US$13.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CCCC
- RA CAPITAL MANAGEMENT, L.P. 8.19M sh · $27.29M · Q3 2026
- Bain Capital Life Sciences Investors, LLC 7.17M sh · $23.88M · Q3 2026
- Boxer Capital Management, LLC 4.15M sh · $13.82M · Q3 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 3.45M sh · $11.50M · Q3 2026
- STEMPOINT CAPITAL LP 3.29M sh · $10.97M · Q3 2026
- HighVista Strategies LLC 873.28K sh · $2.91M · Q3 2026
- PLATINUM INVESTMENT MANAGEMENT LTD 577.53K sh · $1.92M · Q3 2026
More on Lynx1 Capital Management LP
FAQ
How long has Lynx1 Capital Management LP held CCCC?
Lynx1 Capital Management LP has disclosed CCCC holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Lynx1 Capital Management LP's current position in CCCC?
As of Q3 2026, Lynx1 Capital Management LP holds 7.53M shares of CCCC (C4 THERAPEUTICS INC), valued at $25.08M, representing 3.88% of its reported portfolio and ranking #4.
Has Lynx1 Capital Management LP been buying or selling CCCC?
In the latest 13F filing (Q3 2026), Lynx1 Capital Management LP increased its position in CCCC. The position peaked in Q3 2024 at 6.88M shares.
Which other funds hold CCCC?
Other major institutional holders of CCCC include RA CAPITAL MANAGEMENT, L.P., Bain Capital Life Sciences Investors, LLC, Boxer Capital Management, LLC, among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.